FDA Grants Breakthrough Device Designation to Inbiome for Molecular Culture ID Technology in Bacterial Diagnostics

Inbiome has announced breakthrough technology Molecular Culture ID has been granted by the U.S. Food and Drug Administration. 

This grant showcases the FDA's acknowledgment of inbiome's technology and its potential to enhance infectious disease diagnostics.

The Breakthrough Device designation, which is both prestigious and highly competitive, is granted only in exceptional circumstances to devices that provide substantial advancements over current alternatives.

Molecular Culture ID is a new diagnostic test that challenges by integrating advanced chemistry with artificial intelligence to quickly detect and identify more than 200 bacterial species from different bodily samples. 

This groundbreaking technology enables same-day, highly accurate diagnoses, greatly minimizing wait times, enhancing patient outcomes, and reducing healthcare costs.

By improving the diagnosis of serious infections such as pleural, peritoneal, joint, bone, pericardial, and surgical wound infections, Molecular Culture ID marks a significant leap forward in the prompt and effective treatment of bacterial infections.

This achievement will not only improve patient outcomes but also be vital in combating the global challenge of antimicrobial resistance by ensuring the appropriate and effective use of antibiotics.

This aims to ensure that patients and healthcare providers have prompt access to essential medical innovations, aligning with the Agency's mission to safeguard and enhance public health.

 

 

 

Source: https://www.globenewswire.com/news-release/2024/09/26/2953543/0/en/Inbiome-Receives-FDA-Breakthrough-Device-Designation-for-Revolutionary-Molecular-Culture-ID-Technology-Transforming-Bacterial-Diagnostics.html